Top

BMC Pulmonary Medicine

Published in:

Open Access 01-12-2024 | Bronchiectasis | Research

Eosinophilic bronchiectasis increases length and cost of hospitalization: a retrospective analysis in a hospital of southern China from 2012 to 2020

Authors: Chengcheng Lei, Zhimin Zeng, Fengjia Chen, Yubiao Guo, Yangli Liu

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

Background

The concept of eosinophilic bronchiectasis has received clinical attention recently, but the association between blood eosinophil count (BEC) and hospital characteristics has rarely been reported yet. We aim to investigate the clinical impact of BEC on patients with acute bronchiectasis exacerbation.

Methods

A total of 1332 adult patients diagnosed with acute exacerbation of bronchiectasis from January 2012 to December 2020 were included in this retrospective study. A propensity-matched analysis was performed by matching age, sex and comorbidities in patients with high eosinophil count (≥ 300 cell/µL) and low eosinophil count (< 300 cell/µL). Clinical characteristics, length of hospital stay (LOS), hospitalization cost and inflammatory markers were compared between the two groups.

Results

Eosinophilic bronchiectasis occurred in approximately 11.7% of all patients. 156 propensity score–matched pairs were identified with and without high eosinophil count. Eosinophilic bronchiectasis presented with a longer LOS [9.0 (6.0–12.5) vs. 5.0 (4.0–6.0) days, p < 0.0001] and more hospitalization cost [15,011(9,753–27,404) vs. 9,109(6,402–12,287) RMB, p < 0.0001] compared to those in non-eosinophilic bronchiectasis. The median white blood cell (WBC), lymphocyte, platelet (PLT) and C-reactive protein (CRP) levels in eosinophilic bronchiectasis were significantly increased. Multivariate logistic regression analysis confirmed that the high levels of eosinophil count (OR = 13.95, p < 0.0001), worse FEV1% predicted (OR = 7.80, p = 0.0003) and PLT (OR = 1.01, p = 0.035) were independent prognostic factors for length of hospital (LOS) greater than 7 days.

Conclusion

Eosinophilic bronchiectasis patients had longer length of hospital stay and more hospitalization cost compared to those in non-eosinophilic bronchiectasis group, which might be associated with the stronger inflammatory reaction.

Chang AB, Fortescue R, Grimwood K, et al. European respiratory society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021;58(2):2002990. https://doi.org/10.1183/13993003.02990-2020.CrossRefPubMed

Chalmers JD, Elborn JS. Reclaiming the name “bronchiectasis.” Thorax. 2015;70(5):399–400. https://doi.org/10.1136/thoraxjnl-2015-206956.CrossRefPubMed

Amati F, Simonetta E, Gramegna A, et al. The biology of pulmonary exacerbations in bronchiectasis. Eur Respir Rev. 2019;28(154):190055. https://doi.org/10.1183/16000617.0055-2019.CrossRefPubMedPubMedCentral

Shoemark A, Cant E, Carreto L, et al. A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J. 2019;53(6):1900303. https://doi.org/10.1183/13993003.00303-2019.CrossRefPubMed

Giam YH, Shoemark A, Chalmers JD. Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism. Eur Respir J. 2021;58(2):2003157. https://doi.org/10.1183/13993003.03157-2020.CrossRefPubMed

Polverino E, Dimakou K, Hurst J, et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. Eur Respir J. 2018;52(3):1800328. https://doi.org/10.1183/13993003.00328-2018.CrossRefPubMed

Oriano M, Gramegna A, Amati F, et al. T2-high endotype and response to biological treatments in patients with bronchiectasis. Biomedicines. 2021;9(7):772. https://doi.org/10.3390/biomedicines9070772.CrossRefPubMedPubMedCentral

Aliberti S, Sotgiu G, Blasi F, et al. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J. 2020;56(2):2000453. https://doi.org/10.1183/13993003.00453-2020.CrossRefPubMed

Singh D, Brightling C. Bronchiectasis, the latest eosinophilic airway disease: what about the microbiome? Am J Respir Crit Care Med. 2022;205(8):860–2. https://doi.org/10.1164/rccm.202201-0105ED.CrossRefPubMedPubMedCentral

10.

Shoemark A, Shteinberg M, De Soyza A, et al. Characterization of eosinophilic bronchiectasis: a european multicohort study. Am J Respir Crit Care Med. 2022;205(8):894–902. https://doi.org/10.1164/rccm.202108-1889OC.CrossRefPubMed

11.

Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6):1700051. https://doi.org/10.1183/13993003.00051-2017.CrossRefPubMed

12.

Guan W-J, Chen R-C, Zhong N-S. The bronchiectasis severity index and faced score for bronchiectasis. Eur Respir J. 2016;47(2):382–4. https://doi.org/10.1183/13993003.01717-2015.CrossRefPubMed

13.

Dente FL, Bilotta M, Bartoli ML, et al. Neutrophilic bronchial inflammation correlates with clinical and functional findings in patients with noncystic fibrosis bronchiectasis. Mediators Inflamm. 2015;2015:642503. https://doi.org/10.1155/2015/642503.CrossRefPubMedPubMedCentral

14.

Rademacher J, Konwert S, Fuge J, et al. Anti-il5 and anti-il5rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. Eur Respir J. 2020;55(1):1901333. https://doi.org/10.1183/13993003.01333-2019.CrossRefPubMed

15.

Ren J, Chen A, Wang J, et al. Association of blood total immunoglobulin e and eosinophils with radiological features of bronchiectasis. BMC Pulm Med. 2023;23:316. https://doi.org/10.1186/s12890-023-02607-0.CrossRefPubMedPubMedCentral

16.

Uphoff E, Cabieses B, Pinart M, et al. A systematic review of socioeconomic position in relation to asthma and allergic diseases. Eur Respir J. 2015;46(2):364–74. https://doi.org/10.1183/09031936.00114514.CrossRefPubMed

17.

Alsallakh MA, Rodgers SE, Lyons RA, et al. Association of socioeconomic deprivation with asthma care, outcomes, and deaths in wales: a 5-year national linked primary and secondary care cohort study. PLoS Med. 2021;18(2):e1003497. https://doi.org/10.1371/journal.pmed.1003497.CrossRefPubMedPubMedCentral

18.

Evans IES, Bedi P, Quinn TM, et al. Bronchiectasis severity is an independent risk factor for vascular disease in a bronchiectasis cohort. Chest. 2017;151(2):383–8. https://doi.org/10.1016/j.chest.2016.09.022.CrossRefPubMed

19.

Wang X, Villa C, Dobarganes Y, et al. Phenotypic clustering in non-cystic fibrosis bronchiectasis patients: the role of eosinophils in disease severity. Int J Environ Res Public Health. 2021;18(16):8431. https://doi.org/10.3390/ijerph18168431.CrossRefPubMedPubMedCentral

20.

Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107. https://doi.org/10.1002/sim.3697.MathSciNetCrossRefPubMedPubMedCentral

21.

Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest. 2010;138(4):944–9. https://doi.org/10.1378/chest.10-0099.CrossRefPubMedPubMedCentral

22.

De La Rosa CD, Navarro Rolon A, Girón Moreno RM, et al. Cost of hospitalizations due to exacerbation in patients with non-cystic fibrosis bronchiectasis. Respiration. 2018;96(5):406–16. https://doi.org/10.1159/000489935.CrossRef

23.

Joish VN, Spilsbury-Cantalupo M, Operschall E, et al. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a us health plan perspective. Appl Health Econ Health Policy. 2013;11(3):299–304. https://doi.org/10.1007/s40258-013-0027-z.CrossRefPubMed

24.

Hiles SA, Gibson PG, McDonald VM. Disease burden of eosinophilic airway disease: comparing severe asthma, copd and asthma-copd overlap. Respirology (Carlton, Vic). 2021;26(1):52–61. https://doi.org/10.1111/resp.13841.CrossRefPubMed

25.

Greulich T, Tüffers J, Mager S, et al. High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated copd patients - a retrospective analysis. Respir Res. 2020;21(1):106. https://doi.org/10.1186/s12931-020-01365-5.CrossRefPubMedPubMedCentral

26.

Aliberti S, Sotgiu G, Gramegna A, et al. Thrombocytosis during stable state predicts mortality in bronchiectasis. Ann Am Thorac Soc. 2021;18(8):1316–25. https://doi.org/10.1513/AnnalsATS.202002-094OC.CrossRefPubMed

27.

Thomsen M, Dahl M, Lange P, et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(10):982–8. https://doi.org/10.1164/rccm.201206-1113OC.CrossRefPubMed

Title: Eosinophilic bronchiectasis increases length and cost of hospitalization: a retrospective analysis in a hospital of southern China from 2012 to 2020
Authors: Chengcheng Lei
Zhimin Zeng
Fengjia Chen
Yubiao Guo
Yangli Liu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Bronchiectasis
Pseudomonas Aeruginosa
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-024-02912-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

The impact of obesity on ventilator-associated pneumonia, a US nationwide study

Treatment of malignant airway obstruction with Y-shape sigma stent loaded with I125 seeds installed via rigid bronchoscopy

Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention—prospective, single-center, randomized, parallel-group study

Chronic obstructive pulmonary disease burden, grades and erythrocytosis at a tertiary hospital in western Uganda

Do middle-aged patients with onset of idiopathic scoliosis before the age of 10 years who have reduced pulmonary function have a risk for rapid decline – a comparative study

Age at menarche and idiopathic pulmonary fibrosis: a two-sample mendelian randomization study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials